Trafalgar International, Inc. (GCAN) Fair Value 2026

GCAN · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, Trafalgar International, Inc. (GCAN) trades at $0.25. QOC: 3.1/10. Value Trap Risk: 35/100 (LOW). 0/13 models active.

Key Facts

Ticker
GCAN
Price
$0.25
Quality Score
3.1/10
Value Trap Risk
35/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.1/10 signals weak fundamentals

What Fair Value Does Each Model Give GCAN?

0 Intrinsic Value Models vs. Current Price ($0.25)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Trafalgar International, Inc. (GCAN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Trafalgar International, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About GCAN?

0 of 13 models are currently active for GCAN. See which stocks rank higher →

How Does GCAN Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, GCAN ranks #104 by Quality of Company score. CirclFi's QOC score of 3.1/10 evaluates 32 fundamental signals. A score of 3.1 signals below-average fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, Trafalgar International, Inc. competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is GCAN a Value Trap?

CirclFi's Value Trap algorithm assigns GCAN a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Trafalgar International, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Trafalgar International, Inc. is rated at 3.1/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GCAN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Trafalgar International, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

CTTHCTT Pharmaceutical Holdings, Inc.QOC 3.3HCMHUTCHMED (China) LimitedQOC 2.7GREHGreen Rain Energy Holdings Inc.QOC 3.3KMDAKamada Ltd.QOC 2.6NIKANIKA PHARMACEUTICALS INC.QOC 3.5BGMBGM Group Ltd.QOC 1.9HIMSHims & Hers Health, Inc.QOC 7.9EOLSEvolus, Inc.QOC 6.2NTRRNeutra Corp.QOC 5.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: CTTH · HCM · GREH · KMDA · NIKA · BGM · HIMS · EOLS · NTRR · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to GCAN?

7 companies across all industries closest to GCAN’s Quality of Company score of 3.1/10.

ELREYinfu Gold CorporationQOC 3.1YMATJ-Star Holding Co., Ltd.QOC 3.1MGAMagna International Inc.QOC 3.1CLGNCollPlant Biotechnologies Ltd.QOC 3.1SONMDNA X, Inc.QOC 3.1RDCMRADCOM Ltd.QOC 3.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ELRE · YMAT · MGA · CLGN · SONM · RDCM · NVDA

Where Does GCAN Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

GCAN is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Trafalgar International, Inc.’s Valuation?

What is Trafalgar International, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Trafalgar International, Inc. (GCAN). The Quality of Company score is 3.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GCAN overvalued or undervalued right now?

At $0.25, 0 of 0 active models suggest GCAN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Trafalgar International, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 3.1 mean for GCAN?

Trafalgar International, Inc.'s QOC of 3.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on GCAN?

CirclFi analyzes GCAN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is GCAN a value trap in 2026?

Trafalgar International, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Trafalgar International, Inc. (GCAN) a Quality of Company score of 3.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/GCAN/ · Methodology
Primary sources for this GCAN valuation
  • Financial statements: Trafalgar International, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001695473) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GCAN as of ; valuations recomputed .